Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
| 7.03 | |
| 7.03 | |
| - | |
| 7.03 | |
| 7.03 | |
| 5.44-82.4 | |
| 2 609 K | |
| 287 K | |
| 0 | |
| 1.05 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this article, we look at 40 cities with the lowest life expectancy in the US. You can skip our section on developments in the pharmaceutical and biotech industries to enhance longevity and head ove...
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / July 20, 2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the deve...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
